GlassScriptPhysician profile
Nisha Garg
NPI 1164876256
$5,650.65
in general payments reported to CMS, 2019-2025
29 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $325 · 2021: $130 · 2022: $1,401 · 2023: $1,653 · 2024: $1,703 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243 · Travel and Lodging: $474 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68.79 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.63 |
| Travel and Lodging | $474.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68.79 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,367.26 | 2022-2024 | Da Vinci Surgical System |
| Gynesonics, INC. | $564.89 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $452.03 | 2022-2025 | Acessa Provu System |
| Medical Device Business Services, INC. | $325.00 | 2020 | |
| Sumitomo Pharma America, INC. | $254.59 | 2023-2025 | Myfembree |
| Olympus America INC. | $169.13 | 2023-2025 | Olympus, Olympus |
| Aspira Women'S Health INC | $158.16 | 2022-2025 | Ova1 |
| Channel Medsystems, INC. | $135.75 | 2023 | |
| Meditrina | $126.60 | 2025 | |
| Coopersurgical, INC. | $122.36 | 2023 | Vaginal Speculum - Snowman/ Pederson Blade |
| Myriad Women'S Health, INC. | $122.16 | 2023 | Myrisk |
| Myovant Sciences INC. | $118.87 | 2021-2022 | |
| Baxter Healthcare | $93.25 | 2021-2024 | Perclot |
| Abbvie INC. | $90.43 | 2022 | |
| Monaghan Medical Corporation | $85.99 | 2023 | Aerochamber |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $82.84 | 2023 | |
| Applied Medical Resources Corporation | $55.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.13 | 2022-2023 | |
| Pfizer INC. | $37.57 | 2024 | |
| Novo Nordisk INC | $37.29 | 2023-2024 | Wegovy |
| Mayne Pharma Commercial LLC | $34.79 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $27.65 | 2025 | |
| Organon LLC | $26.44 | 2023-2025 | Nexplanon |
| Axonics, INC. | $23.41 | 2023 | Axonics |
| Mycovia Pharmaceuticals, INC. | $19.72 | 2023 | Vivjoa |
| Shield Therapeutics INC | $18.87 | 2023 | Accrufer |
| Intra-Sana Laboratories | $16.08 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Millicent US INC | $15.86 | 2025 | Femring, Intrarosa |
| Boston Scientific Corporation | $14.09 | 2023 | Upsylon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.